There is no single, universally accepted dose of NAD+ or its precursors. However, a growing number of human clinical trials provide useful information on the doses of nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) that have actually been evaluated in studies. These studies help determine which dosage ranges can increase NAD+-related biomarkers, how well individual amounts were tolerated, and whether higher doses consistently lead to stronger functional effects. However, they do not establish a single ideal dose for everyone. Individual response may vary depending on age, health status, metabolism, medications taken, product formulation, and the specific studied effect.
In this guide, we discuss oral doses of NR and NMN used in published human studies, differences in dosage between administration routes, tolerance of larger amounts, and the reasons why increasing the dose does not necessarily mean greater benefits.
We also explain why consulting a doctor or other appropriately qualified healthcare professional regarding NAD+ precursor supplementation is particularly important in the case of co-existing medical conditions or medications being taken.
It is also important to define the scope of this article.
Because oral administration of intact NAD+ faces significant absorption limitations, most human oral dosage studies focus on NAD+ precursors rather than NAD+ itself.
The two best-studied precursors are NR and NMN.
Typical oral NAD+ dosages: starting vs. maintenance dose
In human studies, a fairly wide range of NR and NMN doses was evaluated.
Analysis of the actual doses used in the studies is more useful than a general statement such as „100 to 2000 mg daily,” because the individual amounts led to different changes in NAD+ biomarkers and different study results.
Nicotinamide riboside (NR)
One of the early pharmacokinetic studies in humans evaluated single doses of NR of 100 mg, 300 mg, and 1,000 mg.
All three doses caused a dose-dependent increase in NAD+-related metabolites in the blood. This demonstrated that increasing the amount of NR can lead to progressively greater changes in NAD+ metabolism. [1]
A similar pattern was observed in long-term studies.
In an eight-week, double-blind, placebo-controlled trial involving 140 healthy, overweight individuals, participants received 100 mg, 300 mg, or 1,000 mg of NR daily. [2]
After two weeks, the NAD+ level in whole blood increased by approximately 22% in the 100-mg group, 51% in the 300-mg group, and 142% in the 1000-mg group.
After eight weeks, the increases were approximately 10%, 48%, and 139%, respectively. [2]
No significant difference in the incidence of adverse events was observed between the NR and placebo groups at any of the doses tested.
Another randomized, placebo-controlled crossover trial involved 24 healthy middle-aged and older adults who received 1,000 mg of NR daily for six weeks.
This dose was generally well tolerated, and no serious adverse events were reported.
Researchers also observed a tendency toward lower blood pressure and reduced arterial stiffness, although these results were not sufficient to establish NR as a treatment for cardiovascular diseases. [3]
Some studies used even larger amounts.
NR doses of approximately 2,000 mg per day, often divided into two 1,000-mg doses, were evaluated over a period ranging from several weeks to about three months. [4]
In studies conducted to date, these higher doses have generally not resulted in any significant safety signals.
At the same time, some studies found no significant improvement in the main functional or metabolic parameters assessed, despite marked changes in NAD+ metabolism.
This is an important distinction.
A greater increase in NAD+ biomarkers does not necessarily mean a proportionally greater clinical benefit.
Nicotinamide mononucleotide (NMN)
Human studies have also evaluated a wide range of NMN doses.
In one of the early safety studies in healthy Japanese men, single doses of 100 mg, 250 mg, and 500 mg were evaluated.
At none of these doses did the researchers observe any significant changes in vital signs or routine laboratory test results. [5]
Lower daily doses were also evaluated during longer-term use.
In one of the 12-week studies, 250 mg of NMN was administered daily, and no serious side effects were reported.
Higher doses were used in larger studies evaluating dose-response relationships.
In a randomized, placebo-controlled trial involving 80 healthy middle-aged and older adults, participants received 300 mg, 600 mg, or 900 mg of NMN daily for 60 days. [6]
Blood NAD+ levels increased in a dose-dependent manner in all three NMN-treated groups.
Improvements in the results of the six-minute walk test were also observed in the groups receiving 600 mg and 900 mg.
These functional results are interesting, but they should be interpreted in the context of the specific study, not as proof that such doses will improve physical performance in everyone.
At the upper end of the dose range studied, one of the pharmacokinetic studies used a pharmaceutical-grade microcrystalline NMN formulation.
Participants received either 1,000 mg once daily or 1,000 mg twice daily, for a maximum total of 2,000 mg per day over 14 days. [7]
Both regimens caused a significant, dose-dependent increase in blood NAD+ levels.
The overall incidence of adverse events was similar in the active and placebo groups.
In another four-week safety study, specifically 1250 mg of NMN once daily was evaluated in 31 healthy adults.
This dose was also determined to be well tolerated. [8]
What do these dose ranges mean?
The published literature provides a useful general overview, but does not constitute a formal dosage recommendation.
Lower doses of NR or NMN, approximately 100–300 mg, produced measurable changes in NAD+-related biomarkers in human studies.
The increases were typically smaller than with higher doses.
Doses of approximately 600–1,000 mg per day often resulted in greater changes in NAD+ biomarkers.
In some studies, additional functional outcomes, such as an improvement in the six-minute walk test score, were also observed at these doses. [6]
Doses exceeding 1,000 mg and reaching approximately 2,000 mg per day were also studied.
Over relatively short observation periods, higher amounts were generally well tolerated.
However, they did not consistently lead to proportionally greater functional benefits.
The conclusion best supported by available research is therefore that higher doses may cause greater changes in NAD+ biomarkers, but the relationship between dose and significant health effects is not consistently linear.
Daily or weekly use: what is used in studies?
Almost all published human studies on NR and NMN use daily administration.
Weekly or highly irregular patterns have been studied to a much lesser extent.
Daily protocols typically involve a single daily dose or a dose divided into two portions, often taken in the morning and evening.
This method of conducting research reflects changes in the metabolism of NAD+ precursors over time.
Studies measuring NAD+ during regular supplementation suggest that blood levels of NAD+ may gradually increase and, after about two weeks of consistent daily use, approach a plateau.
After finishing supplementation, the level may drop again.
This pattern supports the hypothesis that regular intake is needed to maintain elevated NAD+-related biomarkers.
However, this does not prove that everyone must take these compounds every day.
More importantly, no adequate human studies have been conducted that directly compare daily dosing with weekly or intermittent dosing.
There is little direct clinical data on regimens such as once weekly or five days of treatment followed by two days off.
Therefore, claims that cyclic use is better, safer, or equally effective remain unconfirmed by direct comparative studies.
If a commercial product recommends an intermittent regimen, this is usually the manufacturer's protocol rather than a dosing regimen established through direct clinical trials.
How does the dosage differ depending on the form of the supplement?
Most of the dosing data discussed above are derived from studies of standard oral capsules or tablets.
This matters because doses cannot be automatically transferred between different delivery methods.
Capsules and tablets
Standard oral capsules and tablets have the most extensive body of human clinical research.
Most clinical trials involving NR and NMN use these conventional oral forms.
The dosage ranges described above therefore apply primarily to products containing NAD+ precursors that are taken orally.
For this reason, research on capsules and tablets currently represents the most clear-cut benchmark when discussing oral doses of NAD+ precursors.
Sublingual products containing NAD+
Sublingual products are designed to dissolve under the tongue.
The intended benefit is that some of the active ingredient can be absorbed through the oral mucosa, thereby partially bypassing the gastrointestinal tract.
This is a sound pharmaceutical concept.
However, adequate human studies have not been conducted to determine whether sublingual NR, NMN, or NAD+ require a lower or higher dose than standard oral capsules to achieve a comparable change in NAD+ levels.
No controlled human study has been identified that directly compares the absorption of the same dose of the precursor administered sublingually versus orally.
For this reason, sublingual dosage instructions are typically established by manufacturers rather than based on confirmed dose equivalence studies.
Liposomal NAD+
Liposomal delivery has slightly more research support than sublingual NAD+.
In a randomized, placebo-controlled trial of a specific liposomal NAD+ formulation, a significant increase in intracellular NAD+ levels was observed after a short period of use.
At the time to which these data refer, however, the study was available as a preprint and had not yet completed the formal peer-review process.
The premise of liposomal delivery is to encapsulate NAD+ in a lipid structure that can protect the molecule during digestion and potentially improve its absorption.
If this mechanism works effectively, a liposomal formulation could theoretically produce a greater biological effect with a lower stated milligram dose than a standard formulation.
However, this has not been confirmed in a peer-reviewed, direct human study comparing equivalent doses of liposomal NAD+ with standard NR, NMN, or non-liposomal NAD+.
Therefore, the NR and NMN doses in capsules described earlier cannot be reliably converted to an „equivalent” liposomal dose.
Intravenous and Injectable NAD+
Intravenous and injectable NAD+ fall into a completely different dosage category.
These routes bypass absorption in the gastrointestinal tract.
Therefore, milligram-for-milligram comparisons with oral NR or NMN are not appropriate.
In a single controlled clinical trial of intravenous NAD+ in a specific patient population, only 10 mg per day was administered for a short period.
This does not mean that 10 mg of intravenously administered NAD+ is equivalent to 500 mg or 1000 mg of oral NR or NMN.
The route of administration, systemic exposure, metabolism, and pharmacokinetics are completely different.
Evidence regarding oral precursors and directly administered NAD+ should therefore be interpreted separately.
What symptoms might indicate that you're taking too much?
NR and NMN generally showed good short-term tolerability in published human studies.
This also applies to studies using doses approaching approximately 2,000 mg per day.
However, good tolerability in a controlled study does not mean that every dose is appropriate for every person.
It also does not confirm the long-term safety of the highest tested amounts.
Some studies have reported mild adverse effects.
They included gastrointestinal discomfort, nausea, changes in bowel habits, headaches, fatigue, and occasional sleep disturbances.
Skin redness may also occur, although this effect is much more strongly associated with high doses of niacin, which is nicotinic acid, than with NR or NMN.
In some studies of NR, symptoms resembling skin redness were also reported.
Importantly, in several studies, a similar frequency of mild symptoms occurred in participants receiving placebo. [2]
This means that the appearance of a symptom during supplementation does not necessarily mean that it was caused by the NAD+ precursor.
However, persistent or worsening symptoms require attention.
Long-lasting nausea, gastrointestinal discomfort, unusual fatigue, sleep disturbances, or other unexpected symptoms may indicate that a given amount or formulation is poorly tolerated.
Discontinuing use of the product and discussing persistent symptoms with an appropriately qualified healthcare professional is more appropriate than assuming discomfort means the product is „working.”.
Commercial products can additionally complicate interpretation, as serving sizes may differ significantly from the amounts evaluated in clinical trials.
Some formulations contain many ingredients.
Others use proprietary blends.
Therefore, before comparing a product with published dosage data, you should check the exact content of NR, NMN, niacin, or nicotinamide.
How to interpret the dose depending on the body's response?
The response to NAD+ precursors varies from person to person.
Clinical trials typically present average results for entire groups rather than predicting the response of each participant.
Therefore, the highest dose used in the study should not automatically be considered the most appropriate for individual use.
Lower doses provide useful information regarding tolerance and biomarker responses.
Studies using approximately 100–300 mg of NR or NMN have shown that these amounts can affect NAD+-related biomarkers. [1,2,6]
Higher doses, particularly in the range of 600–1,000 mg, often resulted in greater changes in biomarkers.
In some studies, additional functional effects were also observed at these doses. [3,6]
The time required to evaluate the response is also important.
NAD+-related biomarkers may fluctuate during the first two weeks or so of regular supplementation.
Assessing a given dose after just one or two days may therefore provide little information about the long-term NAD+ response observed in clinical trials.
Another important rule is simple: more doesn't necessarily mean better.
In several studies using approximately 1,000–2,000 mg per day, NAD+ biomarkers were effectively increased, but improvements were not observed in every functional parameter studied. [4]
This means that the dose-response relationship varies depending on what is being measured.
The level of NAD+ in the blood may continue to rise, while another parameter being measured remains unchanged.
This distinction is important both when interpreting clinical studies and when evaluating marketing claims about supplements.
Why is it a good idea to discuss NAD+ dosing with your doctor?
Most studies on NAD+ precursors have involved relatively well-defined groups of participants.
Middle-aged and older adults are particularly well represented.
Some studies included healthy participants.
Others focused on people who were overweight, obese, or had specific medical conditions.
These results cannot be automatically applied to every population.
A healthcare professional can help assess the extent to which the study populations reflect a person’s individual health situation.
This is particularly important for people with cardiovascular, liver, or kidney diseases, or metabolic disorders.
Some of these states are themselves linked to changes in NAD+ metabolism, and clinical trials of NAD+-related interventions have yielded inconclusive results.
Another issue is the medications being taken.
Formal studies of the interactions between NR and NMN remain limited.
This is particularly important when several supplements or medications that affect glucose regulation, blood pressure, liver metabolism, or other metabolic pathways are used at the same time.
Pregnant and breastfeeding women are also very underrepresented in studies on NAD+ precursors.
Similarly, children and adolescents have not been adequately studied.
The data discussed in this guide do not, therefore, allow for the determination of an appropriate dose for these groups.
The issue of cancer is also more complex.
NAD+ metabolism plays a role in proper DNA repair and cellular function, but NAD+ is also utilized by rapidly dividing cells, including many cancer cells.
Because the relationship between NAD+ metabolism and cancer biology may vary depending on the tissue and the specific disease, individuals with a personal history of cancer or a significant risk of cancer should discuss supplementation with NAD+ precursors with a suitably qualified healthcare professional rather than relying solely on studies involving the general population.
A specialist can also help determine whether a supplement is necessary at all.
Published studies show that NR and NMN may increase NAD+-related biomarkers.
They do not prove, however, that every healthy person will benefit from striving to maximize these biomarkers.
Doses of NAD+ precursors studied in humans
| Association | Sample size | Research context | Main result |
|---|---|---|---|
| NR | 100 mg | Single-dose / pharmacokinetic studies | Increase in NAD+-related metabolites [1] |
| NR | 300 mg | Pharmacokinetic and long-term studies | Higher NAD+ increase than with 100 mg [1,2] |
| NR | 1000 mg | Many human studies | Significant increase in NAD+; generally well tolerated [2,3] |
| NR | Take 2000 mg/day | Research on higher doses | Generally good short-term tolerance; inconsistent functional benefits [4] |
| NMN | 100 mg | Single-dose safety study | No significant clinical safety changes [5] |
| NMN | 250 mg/day | Longer studies involving humans | Generally good tolerance |
| NMN | 300 mg/day | Dose-response study | Increase in blood NAD+ [6] |
| NMN | 600 mg/day | Dose-response study | Greater NAD+ increase; improvement in the walking test was reported [6] |
| NMN | 900 mg/day | Dose-response study | Greater NAD+ increase; improvement in the walking test was reported [6] |
| NMN | 1250 mg/day | Four-week safety study | The dose defined as well tolerated [8] |
| NMN | Take 2000 mg/day | Pharmacokinetic studies | Significant increase in NAD+; similar incidence of adverse events as with placebo [7] |
These values represent the quantities used in the studies.
They are not standardized recommended doses.
Frequently asked questions about NAD+ dosing
How much NAD+ should you take daily?
There is no universally accepted daily dose of NAD+ or its precursors. In human studies, NR and NMN have been evaluated over a wide range, often from about 100 mg to 1000 mg per day, with some studies involving doses reaching about 2000 mg per day. However, these are research protocols, not approved or appropriate individual doses for everyone.
What is the typical dose of NMN in research?
Human studies have evaluated doses of NMN including 250 mg, 300 mg, 600 mg, 900 mg, 1000 mg, and 1250 mg per day, with some short-term pharmacokinetic studies using up to 2000 mg. Blood NAD+ levels generally increased with the dose, but larger amounts did not consistently lead to proportionally greater functional benefits. [6–8]
What is the typical dose of NR in research?
In NR studies, 100 mg, 300 mg, and 1000 mg per day have been frequently used, and some studies have evaluated amounts reaching approximately 2000 mg per day. Higher doses generally led to a greater increase in NAD+ biomarkers, but clinical results varied between studies. [1–4]
Is 1000 mg of NMN too much?
A dose of 1000 mg of NMN has been used in human clinical trials, and some short-term studies have evaluated even higher amounts. [7,8]
However, this does not mean that 1000 mg is suitable for every person, especially since long-term safety data and information for various health conditions remain limited.
Is 1000 mg of NR too much?
In human studies, 1000 mg of NR per day has been evaluated multiple times, and good tolerability has generally been observed over the studied periods. [2,3]
Some studies used up to about 2000 mg per day, but higher amounts did not consistently lead to proportionally greater functional benefits.
Is a higher dose of the NAD+ precursor better?
Not necessarily.
Higher doses of NR or NMN often cause a greater increase in blood NAD+, but several studies have shown that larger biomarker changes do not automatically translate to better metabolic, cardiovascular, physical, or other functional outcomes. [2,4,6]
Should NR or NMN be taken daily?
Most published human studies used daily administration, typically once or twice daily.
Adequate studies directly comparing daily dosing with weekly, intermittent, or cyclic dosing have not been conducted, so claims that schedules other than daily are equally effective or better remain uncertain.
How long do you have to wait for an increase in NAD+ levels?
Human supplementation studies suggest that NAD+-related biomarkers can begin to change relatively quickly and approach a plateau after about two weeks of regular precursor intake.
However, this time may vary depending on the compound, dose, study design, and individual metabolism.
Does sublingual NAD+ work more strongly than capsules?
This has not been confirmed in controlled human studies.
Sublingual products are promoted as a potential absorption-enhancing solution, but there are no reliable dose-equivalence studies showing that a specific sublingual amount provides the same or greater increase in NAD+ than a standard NR or NMN capsule.
Does liposomal NAD+ require a smaller dose?
Theoretically it is possible, but it has not been confirmed.
Liposomal delivery systems are meant to improve the protection and absorption of substances, but there is a lack of peer-reviewed, direct human studies determining the equivalent dose of liposomal NAD+ compared to standard NR or NMN capsules.
Can you take too much NR or NMN?
High doses were generally well tolerated in short-term human studies, but this does not imply unlimited safety.
Some studies have reported mild gastrointestinal discomfort, headaches, fatigue, skin flushing, and sleep changes, while the long-term safety of high daily doses remains insufficiently understood.
Limitations of current research
Most data regarding oral NAD+ dosing comes from NR and NMN studies, not NAD+ itself.
This is due to the limitations in the absorption of orally administered NAD+ and the significantly larger number of studies on precursor supplementation.
Another limitation is the dominance of daily dosing in the clinical literature.
No appropriate direct comparisons were made between daily, weekly, intermittent, and cyclical regimens.
This means that the research provides much more information about regular daily use than about alternative regimens.
Different delivery forms create another gap in the evidence.
The equivalence of sublingual doses with regular capsules has not been established.
Similarly, it is currently impossible to reliably convert capsule doses into liposomal doses.
Although liposomal delivery may affect absorption, robust direct comparative data involving humans remain limited.
The populations participating in the studies are also relatively narrow.
A significant portion of the available research includes healthy, overweight, or obese individuals, as well as middle-aged and older adults.
Children, adolescents, pregnant women, and breastfeeding women are poorly represented or entirely absent from these studies.
Another significant limitation is long-term safety.
Many studies take several weeks or months.
Even if higher doses, such as 1000–2000 mg per day, are well tolerated during such periods, this does not confirm the safety of continuous use of the same amounts for many years.
Finally, biomarker response and functional response are not the same.
Higher doses often result in a greater increase in NAD+-related parameters.
However, they do not consistently lead to greater improvements in physical fitness, metabolism, cardiovascular parameters, cognitive function, or other health outcomes.
Therefore, available studies help determine the ranges of amounts evaluated in humans, but they do not allow for establishing a single optimal oral dose of the NAD+ precursor for every person and every purpose.
Disclaimer
This article is for educational and scientific-informational purposes only. It does not constitute medical advice, individual dosage recommendations, treatment recommendations, or a recommendation for the use of NAD+, nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), niacin, nicotinamide, or any related supplement.
The dose ranges presented in the article describe quantities used in published human studies. They should not be interpreted as approved, optimal, or universally safe daily doses. NAD+ and its precursors are not approved by the FDA or EMA to treat, prevent, or cure any disease, and regulatory status may vary depending on the compound and jurisdiction.
Short-term human studies have generally shown good tolerance to several doses of NR and NMN, including relatively high amounts. However, long-term safety, drug interactions, and proper dosing in many population groups remain insufficiently understood.
References
[1] Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948. https://doi.org/10.1038/ncomms12948
[2] Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://doi.org/10.1038/s41598-019-46120-z
[3] Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. https://doi.org/10.1038/s41467-018-03421-7
[4] Dellinger, R. W., Santos, S. R., Morris, M., Evans, M., Alminana, D., Guarente, L., & Marcotulli, E. (2017). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: A randomized, double-blind, placebo-controlled study. npj Aging and Mechanisms of Disease, 3, 17. https://doi.org/10.1038/s41514-017-0016-9
[5] Irie, J., Inagaki, E., Fujita, M., Nakaya, H., Mitsuishi, M., Yamaguchi, S., Yamashita, K., Shigaki, S., Ono, T., Yukioka, H., Okano, H., Nabeshima, Y., Imai, S., & Yasuda, K. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153–160. https://doi.org/10.1507/endocrj.EJ19-0313
[6] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[7] Pencina, K. M., Lavu, S., Dos Santos, M., Beleva, Y. M., Cheng, M., Livingston, D., & Bhasin, S. (2023). MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults. The Journals of Gerontology: Series A, 78(1), 90–96. https://doi.org/10.1093/gerona/glac049
[8] Fukamizu, Y., Uchida, Y., Shigekawa, A., Sato, T., Kosaka, H., & Sakurai, T. (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific Reports, 12, 14442. https://doi.org/10.1038/s41598-022-18272-y